Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Amit Mahipal, MD
Amit Mahipal, MD, University Hospitals Seidman Cancer Center
Articles by Amit Mahipal, MD
First-line Atezolizumab With Bevacizumab for HCC
Amit Mahipal, MD
Hepatocellular Carcinoma
|
March 13, 2025
Dr. Amit Mahipal discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for HCC.
View More
Dr. Amit Mahipal Discusses Liquid Biopsies for Advanced Cholangiocarcinoma at ASCO GI 2024
Amit Mahipal, MD
ASCO GI 2024
|
March 13, 2025
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
View More
Safety Considerations, Prognostic Factors for Patients with HCC Receiving Lenvatinib After IO
Amit Mahipal, MD
Hepatocellular Carcinoma
|
March 13, 2025
Drs. Mahipal and Finn share the safety and prognostic considerations for patients with aHCC receiving lenvatinib after IO.
View More
Real-world Outcomes for Patients with HCC Receiving Lenvatinib After IO
Amit Mahipal, MD
Hepatocellular Carcinoma
|
March 13, 2025
Drs. Mahipal and Finn discuss real-world outcomes for hepatocellular carcinoma patients receiving lenvatinib following IO.
View More